GeneFerm Biotechnology Co., Ltd. (1796.TWO)
TWD 47.1
(-1.26%)
TWD 47.1
(-1.26%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 190.31 Million | 122.43 Million | 112.23 Million | 56.41 Million | 14.68 Million |
| Net Income | 153.43 Million | 110.21 Million | 70.39 Million | 6.76 Million | -27.55 Million |
| Depreciation & Amortization | 73.48 Million | 50.03 Million | 45.36 Million | 41.06 Million | 37.81 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | 1.53 Million | 3.28 Million |
| Change in working capital | -12.46 Million | -20.56 Million | -16.9 Million | 1.98 Million | 9.77 Million |
| Other non-cash items | -197 Thousand | 6.63 Million | 10.81 Million | 8.05 Million | 63.67 Million |
| Investing Cash Flow | -70.61 Million | -280.32 Million | -145.25 Million | -82.03 Million | -54.56 Million |
| Investments in PPE | -71.4 Million | -278.41 Million | -145.6 Million | -82.32 Million | -54.57 Million |
| Acquisitions | 9000.00 | 39 Thousand | 41 Thousand | 433 Thousand | 13 Thousand |
| Investment purchases | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | 777 Thousand | -1.95 Million | 311 Thousand | -149 Thousand | - |
| Financing Cash Flow | -99.87 Million | -281.78 Million | 224.8 Million | -53.05 Million | 356.85 Million |
| Debt repayment | -31 Million | -234.37 Million | -63.72 Million | -47.66 Million | -372.84 Million |
| Dividends payments | -62.19 Million | -41.46 Million | -3.38 Million | - | -13.89 Million |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | 297.36 Million | - | 2.81 Million |
| Other Financing Activities | -6.68 Million | - | 273.84 Million | - | - |
| Accounts receivables | 4.11 Million | -15.82 Million | -34.51 Million | -7.56 Million | 3.42 Million |
| Accounts payables | -3.22 Million | 193 Thousand | -427 Thousand | 9.39 Million | -886 Thousand |
| Inventory | -9.37 Million | -30.94 Million | -8.13 Million | -7.83 Million | 4.06 Million |
| Other working capital | 10.53 Million | 12.57 Million | 12.16 Million | 5.24 Million | 3.16 Million |
| Cash at beginning of period | 100.69 Million | 539.61 Million | 348.01 Million | 426.28 Million | 110.38 Million |
| Cash at end of period | 120.15 Million | 100.69 Million | 539.61 Million | 348.01 Million | 426.28 Million |
| Capital Expenditure | -71.4 Million | -278.41 Million | -145.6 Million | -82.32 Million | -54.57 Million |
| Effect of forex changes on cash | -359 Thousand | 761 Thousand | -191 Thousand | 408 Thousand | - |
| Net cash flow / Change in cash | 19.46 Million | -438.92 Million | 191.59 Million | -78.26 Million | 315.9 Million |
| Free Cash Flow | 118.91 Million | -155.98 Million | -33.37 Million | -25.9 Million | -39.88 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -6.03 Million | -7.55 Million | 15.21 Million | 153.43 Million | 42.28 Million | 57.85 Million |
| Depreciation & Amortization | 19.92 Million | 20.46 Million | 18.74 Million | 73.48 Million | 18.84 Million | 18.3 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 3.13 Million | 3.24 Million | 15.31 Million | -12.46 Million | -6.01 Million | 25.11 Million |
| Other non-cash items | 15.01 Million | 994 Thousand | -1.36 Million | -197 Thousand | -1.12 Million | 109 Thousand |
| Investing Cash Flow | -2.32 Million | -6.82 Million | -4.86 Million | -70.61 Million | -12.93 Million | -23.48 Million |
| Investments in PPE | -3.02 Million | -5.93 Million | -4.92 Million | -71.4 Million | -12.95 Million | -24.26 Million |
| Acquisitions | 11 Thousand | - | 9000.00 | 9000.00 | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 690 Thousand | -893 Thousand | 47 Thousand | 777 Thousand | 23 Thousand | 784 Thousand |
| Financing Cash Flow | 60.07 Million | 55.75 Million | -37.04 Million | -99.87 Million | -60.78 Million | -8.61 Million |
| Debt repayment | -61.76 Million | -57.25 Million | -35.25 Million | -31 Million | -3.08 Million | -6.91 Million |
| Dividends payments | - | - | - | -62.19 Million | -62.19 Million | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -1.68 Million | - | - | - | - | - |
| Accounts receivables | 21.49 Million | 33.97 Million | -6.87 Million | 4.11 Million | 11.19 Million | 10.04 Million |
| Accounts payables | -2.89 Million | 623 Thousand | 2.04 Million | -3.22 Million | -1.62 Million | -10.29 Million |
| Inventory | -13.88 Million | -2.97 Million | 19.62 Million | -9.37 Million | -6.83 Million | -6.56 Million |
| Other working capital | -1.57 Million | -21.58 Million | 4.53 Million | 10.53 Million | -3.68 Million | 16.85 Million |
| Cash at beginning of period | 185.7 Million | 120.15 Million | 114.87 Million | 100.69 Million | 148.04 Million | 87.54 Million |
| Cash at end of period | 240.53 Million | 185.7 Million | 120.15 Million | 120.15 Million | 114.87 Million | 148.04 Million |
| Capital Expenditure | -3.02 Million | -5.93 Million | -4.92 Million | -71.4 Million | -12.95 Million | -24.26 Million |
| Effect of forex changes on cash | 160 Thousand | 354 Thousand | -388 Thousand | -359 Thousand | 615 Thousand | -698 Thousand |
| Net cash flow / Change in cash | 54.83 Million | 65.55 Million | 5.27 Million | 19.46 Million | -33.16 Million | 60.5 Million |
| Free Cash Flow | -6.11 Million | 10.34 Million | 42.64 Million | 118.91 Million | 26.97 Million | 69.02 Million |
KSI
002156
GLOSTERLTD
HCKT
VOS
5273